PITTSBURGH – LONDON March 15, 2016 - Helomics® Corporation, a privately-held, personalized healthcare company that provides comprehensive tumor profiling utilizing proprietary tissue-based live cell and fixed cell products and services, announced today the launch of GeneFx® Colon, a prognostic multi-gene expression assay designed to identify colon cancer patients who are likely to experience recurrence within five years following initial surgery. GeneFx Colon is designed to enable physicians to make informed personalized treatment decisions about potentially adding adjuvant chemotherapy.
GeneFx Colon is a proprietary gene signature test utilizing an individual patient’s RNA expression and a complex proprietary algorithm. GeneFx Colon is performed on a small amount of tumor tissue, which is removed during surgery or a biopsy, with results available within the average time period for recovery post-surgery. The lab analysis produces a binary test result that categorizes patients as being at either high or low risk of having a tumor recurrence within five years of surgery. Along with the clinical and pathological assessments, GeneFx Colon provides a clear result for risk of recurrence that can help guide physicians with decisions regarding the use of adjuvant therapy in patients with colon cancer.
Neil J. Campbell, President & CEO of Helomics, said, “The GeneFx Colon microarray-based gene signature assay is a strong addition to our portfolio of comprehensive tumor profiling technologies that use both tissue-based live and fixed cell analysis to guide oncology treatment decisions. Our plans are to expand our proprietary offering in the areas of colon cancer. GeneFx Colon analyzes the expression of more than 480 genes, as compared with competitor tests that analyze fewer than 20, to provide the most comprehensive tumor evaluation available. In addition, the clinical utility of GeneFx Colon has been established by five peer-reviewed multi-center prospective and retrospective controlled studies, which showed that use of GeneFx Colon was associated with a significant improvement in patient outcomes measured in terms of overall survival and recurrence-free survival. Based on these studies, we are confident that GeneFx Colon can offer oncologists and patients unprecedented insights when making colon cancer treatment decisions.”
Colon cancer is the second leading cause of cancer mortality among men and women in the United States. The five-year survival rate for individuals with colon cancer is 64.9%. About 80% of colon cancer patients will be cured from surgery alone, however the other 20% of patients will have tumor recurrence. Recurrence in colon cancer arises from micro-metastases that are not observed or visible during primary treatment. Improving risk stratification has great potential benefit for patient care in stage II colon cancer.
About Helomics® Corporation, Inc.
Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular based analysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer. Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit:www.helomics.com.
This release may contain forward-looking statements that involve risks and uncertainties. Market conditions and other important factors could cause actual results to differ materially from those communicated in any forward-looking statements, information disclosed in presentations, conference calls or other public venues. We do not intend to update any forward-looking statements after the date of this press release.